CompletedEUCTR 2011-004676-11
A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia
This historical record does not confirm current site availability.
Historical research recordRomania
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Romania
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 500
- Sponsor
- Janssen-Cilag International N.V.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Romania
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2011-004676-11
- Official title
Show the full official title
A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia
Get this study by email
Recruitment & locations
CompletedRomania
Registry details
Historical country statuses
- Romania — Completed
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International N.V.
Want to explore more studies?
Explore studiesRelated studies
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication
Paliperidone or olanzapine for metabolic effects in schizophrenia